Cargando…

Tolvaptan Add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF): Design and Rationale

BACKGROUND: Diuretic Resistance in Acute Heart Failure (DR-AHF) was designed to demonstrate the effectiveness of the early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in patients with AHF with renal dysfunction and to provide clinical evidence of loop diuretic resistance. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minh, Nhat Giang, Hoang, Hai Nguyen, Maeda, Daichi, Matsue, Yuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829876/ https://www.ncbi.nlm.nih.gov/pubmed/35155599 http://dx.doi.org/10.3389/fcvm.2021.783181

Ejemplares similares

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
por: Ng, Tien M.H., et al.
Publicado: (2020)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

Effectiveness of Yiqi Fumai lyophilized injection for acute heart failure: Rationale and design of the AUGUST-AHF cohort study
por: Zhang, Xuecheng, et al.
Publicado: (2023)

Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction
por: Matsue, Yuya, et al.
Publicado: (2017)

The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF
por: Kagiyama, Nobuyuki, et al.
Publicado: (2018)

Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials
por: Ma, Guang, et al.
Publicado: (2019)

Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status
por: Yamamoto, Tomohiko, et al.
Publicado: (2019)

Tolvaptan: A Novel Diuretic in Heart Failure Management
por: Zulkifli Amin, Hilman, et al.
Publicado: (2016)

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan
por: Kramers, Bart J., et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017)

Status of AHF
por: Swain, G
Publicado: (1988)

Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure
por: Yoshioka, Kenji, et al.
Publicado: (2022)

Loop Diuretics in Clinical Practice
por: Oh, Se Won, et al.
Publicado: (2015)

Novel Intranasal Loop Diuretic
por: Esque, Benjamin, et al.
Publicado: (2023)

Some news on AHF
por: Schaffer, G
Publicado: (1989)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project
por: Pose, Antonio, et al.
Publicado: (2017)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

The Effect of Add-on Acetazolamide to Conventional Diuretics for Diuretic-resistant Edema Complicated with Hypercapnia: A Report of Two Cases
por: Inoue, Tomohiko, et al.
Publicado: (2021)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Larissa Heart Failure Risk Score and Mode of Death in Acute Heart Failure: Insights from REALITY-AHF
por: Xanthopoulos, Andrew, et al.
Publicado: (2023)

Ototoxic effects and mechanisms of loop diuretics
por: Ding, Dalian, et al.
Publicado: (2016)

Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics
por: Iwatani, Hirotsugu, et al.
Publicado: (2022)

AHFS Drug information 2003 /
Publicado: (2003)

Tolerability of bedtime diuretics: a prospective cohort analysis
por: Garrison, Scott R, et al.
Publicado: (2023)

Tolvaptan add‐on therapy in patients with acute heart failure: A systematic review and meta‐analysis
por: Luo, Xiandu, et al.
Publicado: (2020)

Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure
por: Kansara, Tikal, et al.
Publicado: (2022)

Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT‐AHF trial
por: Su, Yang, et al.
Publicado: (2020)

Impact of sex and myocardial function on association of obesity with mortality in Asian patients with acute heart failure: a retrospective analysis from the STRATS-AHF registry
por: Park, Chan Soon, et al.
Publicado: (2020)

A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study
por: Ueda, Shinichiro, et al.
Publicado: (2014)

Loop diuretics association with Alzheimer’s disease risk
por: Graber-Naidich, Anna, et al.
Publicado: (2023)

Cost optimization of the AHF booster energy
por: Craddock, M K, et al.
Publicado: (1988)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Comment on: Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: Rationale and design of SHIFT‐AHF trial
por: Imamura, Teruhiko, et al.
Publicado: (2021)

A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan
por: Takimura, Hideyuki, et al.
Publicado: (2018)

Effectiveness of methotrexate as a second-line treatment for cardiac sarcoidosis assessed via (18)F-FDG PET: a case report
por: Dotare, Taishi, et al.
Publicado: (2022)

Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study
por: Imiela, Tomasz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7cuj1m4n78jh9uqjnsdkhao96u